[{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"Meridian Medical Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Oxford University"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ MERIDIAN MEDICAL TECHNOLOGIES","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ MERIDIAN MEDICAL TECHNOLOGIES"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Patheon Pharmaceuticals Inc.","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Patheon Pharmaceuticals Inc."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"KaliVir Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Vaccinia-based Cancer Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SIGA Technologies \/ KaliVir Immunotherapeutics"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"NIHR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NIHR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NIHR \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NIHR \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"12","companyTruncated":"Meridian Medical Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ ASEAN"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Orthopoxvirus VP37 envelope wrapping protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Tecovirimat
Details :
Tepoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Orthopoxviruses.
Details :
Tpoxx (tecovirimat) is an antiviral drug candidate that targets orthopoxvirus VP37 envelope wrapping protein. It is being evaluated for the treatment of mpox.
Details :
The agreement aims for the procurement of Tpoxx (tecovirimat), an antiviral, approved in the US and Canada for the treatment of smallpox and authorized in EU and the UK for smallpox, mpox and cowpox.
Details :
Tpoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Monkeypox Virus.
Details :
The agreement aims to expand access to Tpoxx (tecovirimat), a novel small-molecule drug for the treatment of smallpox, to the member states in the ASEAN.
Details :
SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Details :
TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Details :
Tecovirimat (also known as TPOXX®) prevents the virus from leaving infected cells, stopping its spread within the body for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers.
Details :
The Company has also demonstrated the ability of NV-387 to encapsulate and improve the pharmacokinetics and pharmacodynamics of a very difficult drug, namely remdesivir, that is formulated in a cyclodextrin-based formulation at present (Veklury® Gilead)...
Details :
TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2022
Lead Product(s) :
Vaccinia-based Cancer Therapy,Tecovirimat
Reset All
